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Since at least two decades, corneal cross-linking by riboflavin and UV-A irradiation stands as 
an established treatment option of progressive corneal ectasia. More than ten years ago, the 
histological evaluation of animal corneas and later of human corneas by means of in vivo bio-
microscopy and scanning laser confocal microscopy demonstrated in corneas treated with 
cross-linking procedure the occurrence of a demarcation line running almost parallel to the 
corneal surface. The feature is a direct consequence of the cross-linking-induced photo-
oxidative modification of the stromal tissue due to riboflavin stromal concentration, light 
distribution within the corneal stroma, riboflavin activation, oxygen availability and diffusion 
in the corneal stroma, radicals release, and UV-A exposure time. In this study, the general role 
of the demarcation line observed after a corneal cross-linking process, in particular its 
mechanical relevance, clinical consequences, and other various findings in the numerous 




Riboflavin-UVA Cross-linking (CXL) represents an innovative therapy changing the 
paradigm of the “conservative” management of progressive Keratoconus (KC) and iatrogenic 
corneal ectasia.1-3 By combined action of 0.1% Riboflavin (photosensitizing agent) and UV-A 
irradiation, this treatment induces release of singlet oxygen that photo-polymerizes stromal 
collagen, reduces the lytic effect of collagenase and increases corneal resistance to 
deformation,1 counteracting certain major pathophysiological mechanisms of KC 
degeneration.4 Long-term clinical studies have shown that CXL treatment with epithelium 
removal (Epi-Off) slows and in over 80% of cases blocks KC progression, with variable 
refractive improvement.5-9 Standard Epi-Off CXL (S-CXL) reduced the need of corneal 
transplants in patients affected by progressive KC or secondary ectasia by 25-30% up to 
50%.10,11 According to unpublished data of the Veneto Italian Eye Bank the advent of CXL 
reduced the percentage of KC requiring a corneal transplant from 5% to 20%, in any case 
delaying the necessity of corneal transplant surgery of at least 5 years. Various modifications 
of S-CXL as originally described by Wollensak et al.1 in 2003 have been proposed in the last 
fifteen years. The so-called demarcation line (DL) visible at the posterior edge of the cross-
linked stroma has been used as a convenient tool for the assessment of the efficacy and safety 
of the new cross-linking procedures. Recently, the role of the DL as an indicator for cross-
linking efficacy has been questioned, opinion which we do not support and consider to be 
unjustified. 
 
Demarcation Line in Epi-Off Standard Fluence CXL 
 
Since the beginning of CXL experience,1,2 a sort of “cutting edge” between the cross-
linked (CX-Linked) and not CX-Linked corneal stroma was demonstrated by histological 
evaluation in rabbit corneas by Wollensak et al.12 The boundary was first established in post-
CXL in vivo animal models corneas by a clear confirmation of keratocytes disappearance 
3 
 
(apoptosis) due to photo-oxidative damage driven by reactive oxygen species (ROS), 
particularly singlet oxygen, delivered during the CXL process, being expression of the 
“correct interaction” between UV-A at 370 nm wavelength, activated 0.1% Riboflavin 
molecules, Oxygen and Collagen-Proteoglycans Complex (CPC) of the corneal stromal 
extracellular matrix (ECM).13 The pivotal histological studies by Wollensak et al 12,13 
described a clear separation between the anterior-mid stroma with lacunar edema and 
apoptosis of keratocytes and the posterior stroma regularly populated by cells nuclei at an 
average depth of 300 µm according to the S-CXL parameters set in the Dresden protocol.1 
Figure 1 a. The stromal depth of the keratocyte apoptosis was clearly correlated with the 
applied surface UV-A irradiance,14 Figure 2.   
Seiler et al15 and Mazzotta et al16,17,18 demonstrated, for the first time in vivo in 
humans by means of biomicroscopy and In Vivo Scanning Laser Confocal microscopy 
(IVCM), respectively, in the first 15 days after S-CXL protocol, the presence of a clear 
transition between an edematous hypo-reflective anterior mid-stroma depleted of keratocytes 
nuclei and a normo-reflective posterior corneal stroma without edema and regularly populated 
by cells, Figure 1 b. Usually the DL gets shallower in the periphery and approaches the 
corneal surface because of the UVA beam profile.19  
The Vertical Transition Area (VTA) between 270 and 330 µm of stromal depth 
described by Mazzotta at IVCM in humans18 was exactly correspondent to the keratocytes 
apoptosis depth described by Wollensak et al12 approximately at 300 µm in in vivo rabbit 
studies, documenting stromal cell apoptosis and lacunar edema with corneal reflectivity 
changes. IVCM pivotal studies16-18 after S-CXL documented that the microstructural changes 
were initially characterized by the presence of a “lacunar” stromal edema associated with 
keratocytes loss, disappearance of sub-epithelial and anterior-mid stromal nerve fibres. 
Moreover, bright micro-particles described as “apoptotic bodies” were also found in a dense 
network of hyper-reflective “trabecular patterned stroma” extracellular matrix (ECM) 
surrounding edematous lacunae.16 Later, between the third and the sixth month after S-CXL, 
“needle-shaped” hyper-reflective micro-bands were documented at IVCM analysis with 
progressive disappearance of corneal edema, associated with gradual keratocytes 
repopulation, sub-epithelial and stromal nerves regeneration with increasing in ECM 
reflectivity. 
The first clinical observation of a “demarcation line” (DL) was reported by Seiler et al 
at corneal bio-microscopy15 as showed in Figure 1 c. Authors observed this clinical feature at 
slit lamp examination of the cornea two weeks after a CXL procedure, representing a “direct 
clinical mark”, additionally to corneal topography, of the morphological changes induced by 




Figure 1. Demarcation Line 15 days after standard irradiance 3mW/cm2 and 5.4 J/cm2 
of energy dose for 30 minutes of UV-A exposure (Dresden Protocol): histology (a white 
arrow), in vivo confocal microscopy (b white arrow), biomicroscopy (c white arrow) and 
corneal OCT (d white arrow). All the morphological (histological, confocal, 
biomicroscopic and OCT) studies agreed that the stromal DL after CXL represents the 
“boundary” between CX-linked and untreated cornea, corresponding to penetration of 
CXL-induced keratocytes apoptosis depth at ultrastructural level, to keratocytes 
apoptosis and stromal edema at in vivo confocal microscopy (IVCM) microstructural 
level, to changes in the refraction index and optical reflection properties of treated 
versus untreated corneal stroma at biomicroscopic examination, to optical interface line 
due to reflectivity changes, different tissue density and light-scattering at OCT.  
Early IVCM analysis after S-CXL procedure16 confirmed in vivo in humans that the 
cytotoxic effect of corneal collagen CXL with the standard irradiance of 3mW/cm2 and 5.4 
J/cm2 of energy dose “fluence” delivered for 30 minutes of UV-A exposure (Dresden 
Protocol) was confined in the upper 300 µm of the corneal stroma (about 350 µm from the 
epithelial surface). The keratocytes apoptosis observed in in vivo confocal scans confirmed 
the preclinical in vivo rabbit studies12 showing that apoptosis was associated with post-CXL 
stromal edema13,14 persisting from 1 to 3 months and reducing progressively its intensity in 
time by application of topical steroid therapy.17,18,20  
Mazzotta et al16,17 described in vivo the CXL-induced microstructural changes characterized 
by the presence of a “lacunar” or “spongy” stromal edema associated with keratocytes loss, 
disappearance of sub-epithelial, and anterior-mid stromal nerve fibres. Bright micro-particles 
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“apoptotic bodies” were also found in a dense network of hyper-reflective “trabecular 
patterned stroma” ECM. Moreover “needle-shaped” hyper-reflective micro-bands were 
documented at IVCM analysis after S-CXL. A clear transition between photo-oxidative 
damage and not CX-Linked stroma without edema, with nerves and regularly populated by 
vital cells nuclei was documented.20  
The postoperative microstructural transition constituted a DL between CX-Linked and not 
CX-Linked stroma as an expression of the CXL penetration was correlated with its physical 
and biochemical impact leading to its well-known biomechanical changes.20 
There was a “perfect match” between the first histological observation by Wollensak et al12, 
the first clinical DL documented by Seiler et al15 and the first IVCM studies by Mazzotta et 
al16, that were also confirmed by corneal optical coherence tomography (OCT) records by 
Kymionis et al21, Figure 1 d. 
 
Figure 2. Comparative view of the lacunar edema and keratocytes apoptosis in the first 
two weeks after S-CXL by means of optical microscopy (a) of a rabbit Cornea 
(Wollensak’s first observation)12,13 and IVCM (b) of human cornea (Mazzotta’s first 
observation).16,17  
The authors of the morphological (histological, biomicroscopic confocal,  and OCT 
scans21) studies agreed that the meaning of stromal DL after CXL represented a “boundary 
line” between CX-linked and untreated cornea, corresponding to penetration of CXL-induced 
keratocytes apoptosis depth at ultrastructural level, to keratocytes apoptosis and stromal 
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edema at in vivo confocal microscopy (IVCM) microstructural level, to changes in the 
refraction index and optical reflection properties of treated versus untreated corneal stroma at 
biomicroscopic examination, to optical interface line due to reflectivity changes, different 
tissue density and light-scattering at OCT.12,15,16,21 Interestingly, a similar DL has been 
reported after chemical burns, in which case it is also associated to keratocyte damage and 
stromal edema dependent on the penetration depth of the chemical burn.22 
Biomicroscopic and corneal OCT identification of the DL, represent simple and 
effective non-invasive clinical-instrumental options easily to monitor the “effective depth” of 
Epi-Off CXL treatment in the daily clinical practice, more accurate than Scheimpflug 
cameras,23 while IVCM is the most powerful diagnostic tool identifying the penetration of 
CXL treatment directly in vivo at cellular level.20 
The DL is undoubtedly the “morphological sign” of CXL stromal penetration generated by 
the CXL-induced photo-oxidative damage itself (e.g. keratocytes apoptosis and corneal 
edema), it is visible at slit lamp due to changes in tissue reflectivity and/or different refraction 
index of the CX-Linked stroma vs not CX-Linked stroma, it is recordable at AS-SD OCT as 
typical expression of the post-CXL stromal light-scattering induced by the different tissue 
density.  
The detection of DL represents also a “therapeutic milestone” in terms of safety, 
demonstrating that S-CXL spared the corneal endothelium, and efficacy, showing that the 
biomechanical effects and increase in tissue stiffness were mainly confined in the anterior 
two-thirds of the corneal stromal layer.18,21,22  
 
The Demarcation Line in Trans-Epithelial Standard Fluence CXL  
 
Various laboratory studies24-29 confirmed the necessity of epithelium removal to 
favour sufficient homogeneous concentration of Riboflavin into the stroma and thus to 
guarantee the efficacy and safety of the CXL method.25,26,27 Laboratory studies by Wollensak 
et al28 on Trans-Epithelial Crosslinking (TE-CXL) have shown 20% of the biomechanical 
efficacy of the S-CXL method involving epithelial removal (e.g. 80% less efficient). Scarcelli 
et al29 Brillouin microscopy studies also documented that after TE-CXL the biomechanical 
stiffening of the corneal stroma was superficial and 70% less than Epi-Off S-CXL. The 
penetration of the (hydrophobic) corneal epithelium by riboflavin (a high molecular-weight 
hydrophilic substance)25 was “facilitated” by different compounds that alter the epithelial 
barrier integrity: preservatives (benzalkonium chloride), surfactants and amino-alcohols such 
as trometamol (TRIS) and anaesthetics like tetracaine.30,31 Nevertheless, the presence of 
epithelium in situ represents a physical barrier for both Riboflavin and UV-A25,26 inducing a 
partial penetration, that for riboflavin results in vivo at 1/4 of the standard riboflavin 
concentration achieved after passive diffusion in Epi-Off S-CXL32 and for the UV-A a 30% 
photo-absorption according to photobiology measurements using the standard 370 nm 
wavelength.33 Moreover, an additional main limitation of the presence of epithelium in situ is 
oxygen consumption, estimated to be at least of 40% of the total corneal oxygen consumption, 




Caporossi et al37,38 proved as a first in IVCM studies after TE-CXL with enhanced 
Riboflavin solutions such as Riboflavin 0.1% plus Dextran 15%, EDTA and TRIS (Ricrolin 
TE®, Sooft, Montegiorgio, Italy) at 3mw/cm2 for 30 minutes, in vivo a superficial impact of 
the treatment showing that apoptosis of keratocytes after TE-CXL was superficial, variable 
and unevenly distributed in the anterior sub-Bowman corneal stroma.35 The typical rarefaction 
of cell nuclei mixed with lacunar edema found in S-CXL was often inhomogeneous, 
moreover the maximum depth of the apoptotic effect was recorded at maximum 100 ± 20 µm 
depth measured from the epithelial surface, Figure 3 a. OCT after TE-CXL detected no DL in 
the majority of cases or a shallower and inhomogeneous DL in 20% of patients, Figure 3 b.  
A systematic IVCM review analysis after CXL20 documented that the most significant 
aspect differentiating TE-CXL and Epi-Off S-CXL on the qualitative confocal microstructural 
plane was that after TE-CXL the apoptosis of stromal keratocytes in vivo in humans was 
superficial, variable and unevenly distributed in the anterior stroma under the Bowman’s 
lamina with a maximum penetration of about 100 µm (measured from the surface of corneal 
epithelium), whereas after Epi-Off S-CXL it was deeper (300 µm under the Bowman’s 
lamina) and more homogeneous. According to Mazzotta et al20 the depth of keratocytes 
apoptosis correlates linearly with CXL penetration DL depth and the biomechanical effect of 
CXL. Moreover, TE-CXL leads to transitory alteration of corneal epithelial cells as showed in 
Figure 3. The toxic effects on the epithelium are related to chemical toxicity of enhanced 
Riboflavin solutions and the associated UV-A photodynamic damage itself causing a diffuse 
superficial punctate keratitis in the first months after treatment as showed in Figure 3 c, with 




Figure 3: IVCM (a) and OCT (b) after TE-CXL. IVCM after TE-CXL with chemically 
enhanced Riboflavin solutions showing that apoptosis of keratocytes is superficial, 
variable and unevenly distributed in the anterior sub-Bowman corneal stroma with a 
maximum depth of the apoptotic effect recorded at 100 ± 20 µm depth measured from 
the epithelial surface (a white arrow). OCT after TE-CXL detected no clear optical DL 
in the majority of cases or a shallower and poorly visible DL in 20% of patients with 
inhomogeneous increased reflectivity (b white arrow). Diffuse superficial punctate or 
striate keratitis in the first months after treatment was documented at biomicroscopy (c 
white arrow) and basal corneal epithelium apoptosis at IVCM (d white arrow).  
The TE-CXL largely showed unsatisfactory mid to long-term clinical results.30,31,38,39 
Leccisotti et al30 documented a limited effect of TE-CXL compared with S-CXL with 
epithelium removal. Koppen et al31 in a cohort study evaluating the efficacy of TE-CXL by 
using proparacaine drops 0.5% plus preserved with BAC 0.005% showed that despite no 
complications or haze, the TE-CXL was not effective in stabilizing progressive keratoconus, 
documenting a statistically significant continuous maximum K increasing and thinnest point 
decreasing (i.e. KC progression) throughout the study. Caporossi et al38 reported an 
unacceptable 50% of retreatments 24-months after TE-CXL in paediatric patients that 
required an additional S-CXL with epithelium removal.  
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In a recent prospective, interventional multicenter cohort study, assessing the efficacy of an 
enhanced Riboflavin solution containing benzalkonium chloride 0.01% for TE-CXL, 
Gatzioufas et al39 confirmed the clinical inefficacy of the of TE-CXL documenting that K 
max, uncorrected and corrected distance visual acuity did not change significantly after 12-
months follow-up and a progression of KC (defined by an increase in K max greater than 1.00 
dioptre) occurring in 46% of treated eyes. Moreover, in analogy with IVCM studies, marked 
punctate corneal epitheliopathy/loose epithelium were observed in 23% of the patients in the 
immediate postoperative period. Even if no adverse events (corneal infection, sterile 
infiltrates, or haze) were observed after this procedure, the 46% of KC progression was 
disconcerting.39 
The factors leading to TE-CXL high percentage of failure ranging from 46% to 
100%31,38,39 in a follow-up between 12 and 24 months are not correlated to its refractive 
impact but reasonably (if not obviously) to its incapacity to sufficiently penetrate in the 
stroma25 allowing a consistent amount of crosslinks distribution, sufficient and deep 
crosslinks saturation thus stabilizing KC progression in the long-term follow-up like the S-
CXL. In the order of importance there are three main limiting factors in the TE-CXL low 
efficacy: the UV-A photo-absorption by antioxidant systems of epithelium,33 the oxygen 
consumption by the epithelium (tenfold higher than stroma),34,35 the halved and 
inhomogeneous intra-stromal riboflavin concentration32 due to the uneven epithelial barrier 
alteration provided by all the chemically enhanced riboflavin solutions available on the 
market.38,39 Due to its marginal impact in the anterior sub-Bowman corneal stroma, the above 
mentioned causes explain why after TE-CXL the DL is invisible in the majority of patients, 
shallower and poorly visible as documented by IVCM keratocytes apoptosis confined in the 
anterior 100 µm of corneal stroma and OCT.20 In this contest, a correlation between DL depth 
and failure rate of TE-CXL remains unquestionable.  
In order to overcome the limitations of the TE-CXL techniques based on chemical 
disruption and uneven alteration of the epithelial barrier, an electricity-assisted methodology 
of riboflavin transport with epithelium in situ, so called Iontophoresis-assisted CXL (I-CXL), 
was developed with promising results with respect to standard CXL.40-46 The purposes of Epi-
On CXL remain the prevention of pain, risk of infectious keratitis and wound healing 
complications related to epithelial removal, with faster recovery and reduced glare disability, 
thus avoiding the necessity to perform CXL necessarily in an operating theatre.  
Early clinical data on I-CXL have shown an increased permeation of the riboflavin into the 
stroma compared to previously mentioned trans-epithelial techniques.32 Clinical data reported 
in literature showed the efficacy of I-CXL in stabilizing KC in the short term follow-up.40-42 
The 24-months follow-up evaluation concluded that I-CXL halted progression of keratoconus 
better than the pharmacological TE-CXL but less efficiently than the standard Epi-Off 
CXL.43,44 Nevertheless, the DL assessed by OCT and IVCM after I-CXL was visible in less 
than 50% of the cases and it was more superficial (150-200µm measured with epithelium) 
than the one of the traditional procedure.45  
However, the percentage of DL observation in I-CXL is twofold the one in TE-CXL (50% 
instead of 25%) as well as the penetration of the photo-oxidative effect (200 instead of 
100µm) even though non homogeneous and still inferior to S-CXL.44,45  
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In this setting, Vinciguerra et al46 removed also the epithelium and after I-CXL imbibition 
improved the efficacy of this CXL technique in both functional and DL detection, regrettably 
loosing the overall advantages of the Epi-On CXL: less pain, reduced corneal infectious risk 
and CXL-wound related complications. 
Mazzotta et al45 recently published a new Iontophoresis protocol called Enhanced Fluence 
Pulsed-light Iontophoresis (EF-ICXL) showing promising 12-months follow-up reduced 
maximum keratometry, corneal surface asymmetry indices and higher-order aberrations. This 
new protocol improved the visibility of DL in over 80% at 285 ± 20 μm depth on average, 
increased the penetration of photo-oxidative damage improving the photochemical kinetic of 
the original I-CXL technique by increasing of 30% the treatment fluence (from 5.4J/cm2 to 
7J/cm2) compensating the UV-A energy photo-attenuation provided by the corneal epithelium 
and Bowman’s layer antioxidants systems, Figure 3.   
 
Figure 3. Demarcation Line after Mazzotta’s Enhanced Fluence Pulsed Light 
Iontophoresis (EF I-CXL). Increasing of 30% the treatment fluence (from 5.4J/cm2 to 
7J/cm2) thus compensating the UV-A energy photo-attenuation provided by the corneal 
epithelium and Bowman’s layer antioxidants system and adding the pulsed light 
partially compensating the 40% estimated oxygen consumption by the corneal 
epithelium in situ, the DL is detectable in over 80% at 280 ± 20 μm depth on average, 
increasing the penetration of photo-oxidative damage improving the photochemical 
kinetic of the original I-CXL technique.  
The variability and unpredictability of collagen and ECM collagen-proteoglycans 
redistribution after CXL may partially explain the non-linear correlation between DL depth 
and functional results.47 Indeed, there is no linear correlation between the depth of DL and the 
functional results after CXL but there are incontrovertible evidences that the best 
postoperative clinical response in the sense of long-term ectasia stabilization was statistically 
and practically achieved after S-CXL with epithelium removal where the DL was deeper and 
detectable in over 90% of patients.48 Moreover, though the CXL is not a refractive procedure 
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but it has long-acting unpredictable refractive impact on the cornea, the treatment’s goal is the 
stiffening of the corneal structure achieving a long-term, possibly irreversible biomechanical 
stabilization of the progressive ectatic diseases. The fundamental ex vivo and in vivo CXL 
studies clearly demonstrated that the best biomechanical stability can be achieved if the 
photo-oxidative process includes a sufficient volume of corneal stroma of at least 2/3 of the 
baseline stromal thickness.48-50  
 
The Demarcation Line in Standard Fluence A CXL Protocols  
 
Since the Epi-Off S-CXL procedure required long treatment time (1 hour 
approximately)24, accelerated crosslinking (A-CXL) protocols have been proposed to shorten 
the duration of the procedure improving patient’s comfort.51-63  
According to equal dose principles stated in the BunsenRoscoe’s Law of reciprocity64, by 
setting the UV-A power at 9mW/cm2 × 10 min, 30mW/cm2 × 3 min, 18mW/cm2 × 5 min, 
45mW/cm2 × 2 min while maintaining a constant fluence of 5.4J/cm2 the same photochemical 
effect as the conventional Dresden protocol at 3mW/cm2 for 30 min could be theoretically 
achievable.65  
As an adjunctive enhancement, facilitating the CXL photodynamic reaction in A-CXL, recent 
laboratory studies by Kamaev et al51 highlighted the importance of intraoperative oxygen 
diffusion into the corneal stroma demonstrating that by pulsing the ultraviolet-A (UV-A) light 
radiation light (1 second ON/1 second OFF), CXL efficiency may be improved allowing 
partial oxygen re-diffusion during the UV-OFF pauses. This kinetic mechanism was also 
described as “dark phase amplification”.  
Touboul et al66 demonstrated that by using a continuous light UV-A exposure in A-CXL with 
30mW/cm2 the average DL depth was found at 150 ± 20 µm. Mazzotta et al67 confirmed this 
finding in vivo by means of IVCM after 30mW/cm2 continuous light irradiation A-CXL, 
Figure 4 a - b, and documented for the first time that fractionating the UV-A exposure by 
pulsing the light (1 second on/1 second off) an enhancement of CXL penetration can be 
achievable increasing the depth of DL by a mean of 50 ±20 µm of depth as documented by 
corneal OCT and IVCM photo-oxidative keratocytes damage, Figure 4 c - d.  
This finding was also confirmed by Moramarco et al68 and Peyman et al69 evaluating corneal 
OCT scans in the same A-CXL protocol. These results proved the consistency of the kinetic 
models provided by Kamaev et al51 demonstrating that by pulsing the UV effectively 
increases intraoperative oxygen diffusion and the penetration of CXL apoptotic effect 
reasonably due to the enhanced amount of singlet oxygen formation.  
Jiang et al70 documented that the DL depth in the pulsed light 30mW/cm2 A-CXL group was 
201 ± 27 µm at 1 month postoperatively confirming Mazzotta’s first observation67 as showed 
in Figure 4 c - d. The study revealed keratocyte apoptosis and stromal edema at 1 month 
postoperatively, which gradually recovered towards the normal status with no changes in the 
posterior stroma and endothelium. Pulsed light A-CXL71 was safe and effective procedure in 
stabilizing the progression of keratoconus and by comparing the S-CXL, where the DL depth 
was 284.94±33.29 µm, authors obtained more effective visual and topographic outcomes than 
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with pulsed light 30mW/cm2 A-CXL group. A correlation between DL depth and clinical 
efficacy was documented.70,71 The pulsed light A-CXL ensured a shorter treatment time, 
increased the average penetration of the DL from 150 µm of the continuous light to 200 µm 
and reduced postoperative microstructural damage thus limiting stromal wound healing 
reactivity. 67,70,71  
Substantially, the kinetic models after S-CXL and A-CXL protocols confirmed that there is a 
faster oxygen depletion and a slow oxygen replenishment shifting the CXL photodynamic 
reaction predominantly in the type I. It happens also in the standard protocol with continuous 
light UV-A exposure because of the fast oxygen consumption (10-15 sec) during the UV-ON 
phase.51 
A preclinical laboratory study conducted by Krueger et al72, evaluating the biomechanical 
efficacy of high versus standard irradiance and pulsed light CXL with equivalent energy dose 
(5.4J/cm2), demonstrated that riboflavin 0.1% with 15mW/cm2 UV-A exposure was as 
effective as conventional 3mW/cm2 CXL and 9mW/cm2 A-CXL in biomechanical 
strengthening of the cornea. Also this study established that pulsed UV-A delivery should 
improve the degree of cross-linking, especially with the faster higher-irradiance exposures 
where oxygen is more quickly consumed.51,72 
As for biomechanical model studies49,50, the CXL treatment should cover at least 200 μm of 
corneal stroma to be stronger conferring a durable strength to corneal stroma. Contradictory 
results are reported in the literature after different A-CXL protocols by using 9mW/cm,2 
18mW/cm2 and 30mW/cm2 UV-A power. However, according to Lang et al,63 with respect to 
either accelerated protocols the standard protocol (S-CXL) showed at 12 months significant 
improvements in a larger number of parameters.52-62 A-CXL with irradiance of 9mW/cm2 for 
10 min52 was demonstrated to be effective in stabilizing topographic parameters after 12-
month of follow-up in mild-moderate keratoconus-affected corneas. Improvement in the 
UDVA and stabilization of all tested corneal parameters were noted after the treatment. 
Moreover, the 9mW/cm2 A-CXL was safe for corneal endothelium, stabilizing the 
progression of keratoconus and iatrogenic ectasia with a significant reduction in topographic 
keratometry values and a significant increase in CDVA, comparable with conventional 
3mW/cm2 CXL in a mid-term (two-years) follow-up.63  
Mazzotta et al73 documented the clinical and microstructural IVCM and OCT results of 
accelerated 15mW/cm2 pulsed-light corneal crosslinking (CXL) in progressive KC showing a 
distinct DL at 280 ±30 µm depth on average. The 15mW/cm2 pulsed-light epithelium-off A-
CXL confirmed the laboratory data of Krueger et al72 demonstrating the safety and the clinical 
efficacy of this protocol in stabilizing KC progression through 2 years of follow-up. However, 
none of these protocols have long-term follow-up, Figure 4 e - f. 
Mazzotta et al74 demonstrated by means of comparative corneal OCT and IVCM scans that 
the DL depth achievable after the 9mW/cm2 A-CXL protocol with 5.4J/cm2 fluence and 10 
minutes of continuous light UV-A exposure was at 310 ± 30 µm depth on average measured 
from the epithelial surface, Figure 4 g - h, nearer to S-CXL 3mW/cm2 Dresden protocol (350 




Figure 4. DL depth determined by spectral domain corneal OCT and comparative 
photo-oxidative damage documented by scanning laser IVCM after different 
Accelerated CXL protocols at standard fluence of 5.4J/cm2. 30mW/cm2 x 3 min UV-A 
continuous light, 150 ± 20µm (a-b); 30mW/cm2 x 6 min UV-A pulsed light (1 sec on 1 sec 
off), 200 ± 30µm (b-c), 15mW/cm2 x 12 min UV-A pulsed light (1 sec on 1 sec off), 280 ± 
30µm (e-f); 9mW/cm2 x 10 min UV-A continuous light, DL 310 ± 30 µm (g-h); 3mW/cm2 
x 30 min continuous light, 350 ± 30 µm (i-l).  
In a recent study Hashemi et al60 documented that A-CXL with 18mW/cm2 UV-A power 
showed less topographic flattening compared with conventional CXL. Refractive and visual 
results of the A-CXL by using continuous light and pulsed light treatment at 30mW/cm2 gave 
similar results compared to conventional 3mW/cm2 CXL after 12-months follow-up. All the 
protocols giving similar results compared to 3mW/cm2 were using a power in the range 
between 9mW/cm2 and 18mW/cm2, demonstrating similar clinical outcomes, sometimes less 
flattening compared to standard 3mW/cm2.63 
 
The Demarcation Line in Enhanced Fluence A-CXL Protocols 
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Roy et al75 firstly proposed Topography guided A-CXL as a potential approach to 
improve the optical predictability of CXL and maximize the corneal regularization using a 
computational patient specific model of keratoconus progression and differential responses to 
CXL. In simulations comparing broad-zone CXL treatments and focal, cone-localized 
treatments, for a variety of patients cone-localized patterns presented in tomography 
examinations larger reductions in the cone curvature and higher order aberrations (HOA).  
According to Roberts et al76, given that corneal ectasia is driven by “focal” rather than 
generalized weakness, focal stiffening of the cone region may promote a more favourable 
material property redistribution with compensatory steepening of surrounding areas, thereby 
enhancing topographic normalization.  
In 2016 Seiler et al77 and Mazzotta et al78 carried out for the first time in Europe the 
Topography-Guided A-CXL with the KXL II™ UVA illuminator (Avedro, Waltham, MS, 
USA), using a 30 mW/cm2 UV-A power with pulsed light emission (1 second on/ 1 second 
off) and enhanced fluence (7.2 J/cm2, 10 J/cm2 and 15 J/cm2) associated to the maximum 
corneal curvature. Experimental KC treatments were planned individually by means of a 
dedicated software (Avedro’s Mosaic System version 1.0, Avedro Inc., Waltham, MS, USA), 
as suggested by the preoperative topography data, Figure 5. The 30 mW/cm2 topography 
based A-CXL treatments consisted in a differentiated energy dose release according to the 
corneal curvatures of each keratoconus. The 7.2 J/cm2 entry level energy dose was delivered 
as broad beam treatment by using 30mW/cm2 UVA power and pulsed (1sec on/1 sec off) light 
illumination for 8 min exposure time. Then, KC areas showing a corneal curvature in the 
range 48 to 52 D were treated with 10 J/cm2 energy dose, keeping the 30 mW/cm2 UV-A 
power, extending the exposure time by 3 min in order to reach the programmed dose of 
10 J/cm2 (reaching 11 min total exposure time), and masking the peripheral area of the KC 
that just received the 7.2 J/cm2 energy dose. The paracentral or central steepest area, with a 
curvature above 52 D, was treated by extending further the UVA exposure time to deliver the 
15 J/cm2 maximum energy dose, reaching 6 min total treatment time. The treatment planning 
was established by using semi-meridians K values on Pentacam maps. The total treatment 
time was 8 min for keratoconus with maximum K values not larger than 48 D, 11 min for 
keratoconus with K values in the steepest area, including simulated, in the range 48 to 52 D, 
and extended to 16 min for keratoconus showing in the steepest areas K values above 52 D. 
The treatment started from a baseline broad beam illumination that included the flattest 
peripheral areas (48 D and below) at 7.2 J/cm2. After 8 min, peripheral areas were masked and 
the illumination was prolonged only in the steepest zones to deliver a final energy dose of 10 J 
or 15 J/cm2, depending on the maximum curvature values. The thinnest point and the area of 
major posterior elevation were included within the highest dose treatment zone. The 
irradiation patterns shapes included arc, circular, oval and combined patterns, according to 
keratoconus tomography and shape. The irradiation pattern was aligned by using a direct real 
time visualization of the cornea, maintaining a perfect centration with the eye-tracking system 
provided by the machine. Corneal OCT scans of the same cornea showed multiple local DL, 
dependent on the irradiance delivered over the corneal tissue and the exposure time. The 
studies on Topography-Guided ACXL by Seiler et al77 and Mazzotta et al78 demonstrated that 
the DL is also function of the irradiance, the treatment time, the concentration of riboflavin, 




Figure 5. Topography Guided A-CXL showing the depth of DL depending on Enhanced 
Fluence and exposure time. After 8 min of UV-A exposure time at 30mW/cm2 with 
pulsed light illumination (1 sec on/1sec off) delivering 7.2 J/cm2 in a broad beam spot of 
9 mm, including the peripheral flattest area of the cone, the depth of DL measured from 
epithelial surface was 200 ± 20 µm (white arrows) in the flatter corneal area; 250 ± 20 
µm in the intermediate curvature paracentral area between 48 and 52 D undergoing 
10J/cm2 fluence and 11 minutes of UV-A exposure time (green arrow); 330± 20 µm (red 
arrow) in the central steeper cone area undergoing 15J/cm2 for 16 minutes of UV-A 
exposure. The increased depth of DL in the paracentral and central areas was correlated 
with the prolonged exposure times (11 and 16 min respectively) necessary to deliver 10 
and 15 J/cm2 fluence. 
After 30 mW/cm2 with 7.2 J/cm2 enhanced fluence pulsed light (1 sec on 1 sec off) A-
CXL, Böhm et al79 observed a mean stromal DL at a depth of 203.00 μm ± 13.53 (SD) and 
concluded that, by increasing the fluence and using the pulsed light while increasing the 
exposure time from 3 to 4 minutes (to 8 minutes in pulsed light enhanced fluence protocol), 
the depth of DL increases, confirming the pivotal OCT and IVCM studies on A-CXL.67,80  
Mazzotta et al81 published recently a new Iontophoresis protocol with an Enhanced 
Fluence Pulsed-light Iontophoresis (EF-ICXL) showing a promising 12-months follow-up 
characterized by reduced maximum keratometry, corneal surface asymmetry indices, and 
higher-order aberrations. The new protocol improved the visibility of DL in over 80% at 285 
± 20 μm depth on average and increased the penetration of photo-oxidative damage, by 
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enhancing the photochemical kinetic of the original I-CXL technique with a 30% increase of 
the treatment fluence (from 5.4J/cm2 to 7J/cm2) in order to compensate the UV-A energy 
photo-attenuation provided by the corneal epithelium and Bowman’s layer antioxidants 
systems, Figure 6. 
  
Figure 6. Demarcation Line after Mazzotta’s Enhanced Fluence Pulsed Light 
Iontophoresis (EF I-CXL). Increasing of 30% the treatment fluence (from 5.4J/cm2 to 
7J/cm2) thus compensating the UV-A energy photo-attenuation provided by the corneal 
epithelium and Bowman’s layer antioxidants system and adding the pulsed light 
partially compensating the 40% estimated oxygen consumption by the corneal 
epithelium in situ, the DL is detectable in over 80% at 280 ± 20 μm depth on average, 
increasing the penetration of photo-oxidative damage improving the photochemical 
kinetic of the original I-CXL technique.  
The pulsed-light irradiation was added to partially increase the intraoperative oxygen 
diffusion and treatment penetration according to literature data.51 These two modifications of 
the original I-CXL protocol allowed a superior and repeatable visualization of the DL that 
was considered an advance in the recent view on trans-epithelial CXL. The preliminary data 
observed in the study were closer to S-CXL evidences, in absence of wound related 
complications (haze) and/or endothelial damage. Of course long-term data in larger cohorts of 
patients will clarify if the crosslinks amount, distribution and saturation will be sufficient to 
maintain a long-term stability similar to Epi-Off S-CXL.81 
Interestingly, Kannellopoulos et al82 showed a DL depth closer to 250 µm from the 
epithelial surface by calibrating a fluence of 6.3 J/cm2 at the corneal surface setting a UV-A 
power of 7 mW/cm2 for 15 minutes.  
In analogy with the same principles of the Enhanced Fluence I-CXL protocol, Kymionis et 
al53, in evaluating the stromal DL depth following a modified accelerated (A-CXL) procedure 
by using 18mW/cm2 UV-A power, with an enhanced fluence of 7.5 J/cm27 for 7 minutes of 
UV-A exposure time instead of standard 5.4J/cm2 for 5 minutes, demonstrated that increasing 
the fluence and consequently the UV-A exposure time by 30-40%, the depth of DL was 
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similar to the one of S-CXL. However, whether accelerated CXL procedures warrant a 
sufficient crosslinks amount, distribution and saturation to maintain long-term stability similar 
to Epi-Off S-CXL remains an open question.  
 














Yam-JRS-2013 262 3 30 
  
Yam-JRS-2012 241 3 30 
Thorsrud-JCRS-2017 237 3 30 
Ng-Cornea-2015 295 3 30 
Asgari-JCurrOphthalmol-2018 315 3 30 
Awwad-AJO-2019 282 3 30 
Doors-AJO-2009 273 3 30 
Brittingham-IOVS-2014 283 3 30 
Bouheraoua- IOVS-2014 263 3 30 
Mesen-Cornea-2018 295 3 30 
Mazzotta-AJO-2008 260 3 30 
Kymionis-JCRS-2014 310 3 30 
Kymionis-Cornea-2013 270 3 30 
Kymionis-AJO-2014 298 3 30 
Knutsson-BJO-2018 209 3 30 
Cerman-JCRS-2015 227 3 30 
Shetty-AJO-2015 240 3 30 
Average 268   1.18 1.00 
Ng-Cornea-2015 203 9 10   
Kymionis-JCRS-2014 248 9 10 
Brittingham-IOVS-2014 205 9 10 
Pircher-Graefe-2018 200 9 10 
Shetty-AJO-2015 252 9 10 
Average 221   1.14 0.93 
Mesen-Cornea-2018 265 18 5   
Asgari-JCurrOphthalmol-2018 183 18 5 
Shetty-AJO-2015 163 18 5 
Average 204   1.03 0.75 
Bouheraoua- J Vis Exp-2015  144 30 3   
Shetty-AJO-2015 161 30 3 
 153   0.78 0.34 
Celik-JCRS-2012 80 45 2 0.70 0.21 
Estimated 15 90 1 0.62 0.08 
 
Table 1: Compilation of depths of the DL for several irradiances by a fluence of 5.4J/cm² 
and of riboflavin 0.1 % concentration. The depth of the DL does not include the 
thickness of the epithelium. 
Asgari et al83 reported a lot of values for the depth of DL for several irradiances, see 
Table 1. From these DL depths the relative DL was calculated as 
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Rel DL =  𝐷𝐷𝐷𝐷
𝐷𝐷𝐷𝐷3
 
where DL is the depth at a specific irradiance, and 𝐷𝐷𝐷𝐷3 is the depth of DL at 3 mW/cm2 for 30 
min (standard CXL with a fixed dose of 5400 mJ/cm2) according to the Dresden protocol DL 
outcome assumed as benchmark12-16 . Figure 8 shows the dependence of the average values of 
the relative depth on the irradiance. 
 
Figure 8: Mean values of relative depth of DL as a function of the irradiance, according 
to experimental data from the literature, see Table 1.  
By means of ex-vivo inflation tests on rabbit corneas, Bao’s84 measured the average elastic 
modulus (E-modulus) for irradiances within the range 3 to 90 mW/cm². Starting from these 
results, the relative increase of the E-modulus due to CXL was estimated according to the 
following expression Rel 𝐸𝐸 =  𝐸𝐸 − 𝐸𝐸0
𝐸𝐸3 − 𝐸𝐸0
 
where 𝐸𝐸0 = 0.57 MPa84 is the average elastic modulus of untreated corneas, 𝐸𝐸3 the average 
elastic modulus of corneas treated with 3 mW/cm2 irradiance for 30 min (standard CXL with 
a fixed dose of 5400 mJ/cm2) and 𝐸𝐸 the E-modulus at the generic irradiance. The relative 





Figure 9: Relative increase of the corneal elastic modulus as a function of irradiance 
(values determined according to experimental measurements of Bao et al76). The Bunsen-
Roscoe law is not valid, otherwise the relative increase of Young´s modulus would be 1 for all 
equivalent UVA doses. 
Figure 10 shows the dependence of the relative value of the elastic modulus on the relative 
DL depth, characterized by a strong nonlinear dependence of the relative stiffness increase of 
the corneal material induced by CXL and the depth of the demarcation line. 
 
Figure 10: Overall CXL biomechanical effect in terms of relative increase of the elastic 
modulus E on the relative depth of D driven by the irradiance.  
The diagram is a clear visualization of the biomechanical effects of the CXL. The result of 
Scarcelli et al27, i.e., TE-CXL with an DL =100µm (Rel D L= 0.37) shows about 70% lower 
efficacy than standard CXL, is confirmed here. From this curve it is also possible to estimate 






Starting from the original S-CXL protocol described by Wollensak et al. in 20031, the 
so-called DL occurring at the posterior edge of the CX-Linked stroma has been universally 
accepted as “therapeutic milestone” and has been considered an appropriate tool for the 
assessment of the effectiveness and safety of CXL procedures.  
Critical reviews of basic laboratory and clinical CXL studies about the DL, in terms of 
relative DL depth and the relative CXL-induced change in the average corneal E-modulus, 
show that a deeper DL is associated with a higher amount and saturation level of crosslinks 
and a more marked stiffening effect (Figures 8, 9, 10). Furthermore, clinical studies report 
that, at a deeper DL, a more durable ectasia stability occurs, often accompanied with a 
stronger corneal flattening.  
By taking the irradiance at 3 mW/cm2 for 30 min (5400 mJ/cm2 dose) as reference, the 
relative DL depth and the relative increase of the corneal E-modulus are asymptotic functions 
of the irradiance (Figures 8, 9). A saturation occurs in the relative DL depth, showing that the 
best penetration and corneal stiffening is achieved at low irradiance and long times.  
By expressing the dependence of the relative change in E-modulus on the relative depth of the 
DL, the resulting non-linear function confirms the existence of a marked correlation between 
the depth of the DL and the biomechanical behaviour of the stromal tissue, see Figure 10, 
although a correlation with post-CLX functional results cannot be directly established. 
The deeper the apoptosis at IVCM and optical interface line at bio-microscopy and OCT, the 
higher is the volume of CX-linked stroma, the higher is the amount (%) of crosslinks, the 
higher the increase of biomechanical stiffness conferred to the corneal stroma. The non-linear 
biomechanical correlation can be explained by the saturation and homogeneity of crosslinks 
distribution into the stroma, that depends on many factors other than the DL depth.  
The strong motivation that promoted the DL concept is that it can be used to assess the 
performance of CXL procedures in terms of biomechanical efficacy and safety without the 
need of conducting extensive invasive experiments. This feature represents also the main 
advantage of the DL concept itself. 
It is well known that CXL is an oxygen dependent reaction. The amount of singlet oxygen 
depends on the energy transfer from the activated riboflavin to the oxygen and, therefore, on 
the oxygen concentration in corneal stroma available for this transfer. The epithelium in situ 
and the presence of antioxidants systems (radical absorbers) decrease the CXL amount by 
diminishing the availability of oxygen and absorbing a portion of the UV-A light. With no 
oxygen, no stiffening effects are possible, although no direct correlation between the 
percentage of oxygen reduction and percentage of stiffening reduction has been established 
yet.  
The occurrence of DL is a direct morphological sign of performed CXL and is a fact 
confirmed by histology, IVCM, bio-microscopy and OCT. This feature is validated in the 
majority of CXL protocols, and depends on the protocol used and accuracy of the CXL 
technique application. The DL is the clear evidence of the CXL-induced photo-oxidative 
tissue modification derived from riboflavin stromal concentration and gradient of 
concentration, light distribution within the stroma and riboflavin activation, oxygen 
availability and diffusion, radical release, and UV-A exposure time (the longer the deeper 
DL). Moreover, the DL is a function of irradiance, treatment time, concentration of riboflavin, 
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depletion of riboflavin, and oxygen. If, after CXL, the DL is detected, it can be taken as a 
positive indicator that the interaction among UV, riboflavin and oxygen was successful. 
Not fortuitously, with respect to the conventional Dresden CXL protocol, the DL measured 
through of higher-resolution spectral domain (SD) corneal OCT was shallower, or less 
detectable, after Epi-On treatments and A-CXL protocol. 
The variability of the complex distribution of collagen and ECM collagen-proteoglycans 
redistribution and the uneven collagen compaction and rearrangement associated with the 
changes in the refraction index of the cornea after CXL protocols may explain the non-linear 
functional correlation between DL depth and changes in visual acuity documented in recent 
studies by Pircher et al77 and Mesen et al78. 
Records of topographic changes in KC after CXL are more complex and depend on cone 
localization or eccentricity, age, baseline visual acuity and baseline thinnest pachymetry, 
status of epithelium, and lacrimal fluid on the corneal surface, together with accuracy of the 
instrumental measurements, and consistency and comparability of collected data.79-81  
Indeed, no statistically significant differences in topographic/refractive results between the 
different CXL protocols, A-CXL protocols and Epi-On protocols are observed. Literature 
reports on various CXL protocols have been presenting comparable results with no 
statistically significant differences, even though corneal flattening measurements achieved 
after Epi-On CXL, I-CXL and A-CXL were often inferior to K max flattening and visual 
acuity recorded after Epi-Off S-CXL.50  
According to Uysal et al82, the optical performance of the cornea following CXL gained an 
improvement in visual, refractive, topographic, and most corneal higher-order aberrations 
(HOAs) outcomes. In addition to the maximum Keratometry flattening, not appropriate to 
reflect the global corneal changes induced by CXL because is a local parameter relative to a 
single point, significant improvements in mean Root Mean Square (RMS) error values for 
corneal total HOAs, vertical coma and vertical trefoil following CXL were reported. Such 
results, though, cannot be considered predictable in CXL. The only functional predictability 
of CLX confirmed by literature data is restricted to the preoperative baseline thinnest 
pachymetry (less than 450μm), which was found to be significantly associated with higher 
flattening in maximum keratometry. 
Recent studies by Mathews et al83, correlating the corneal densitometry after CXL to visual 
acuity, demonstrated that, although the greatest and most durable post-CXL densitometry 
change was in the anterior layer, the degree of increased densitometry haze in the mid-stromal 
layer was mostly associated with (possibly predictive factor) improvement in CDVA, 
maximum K, and HOAs. The persistence of corneal haze at 6 months, measured by increased 
densitometry, might be a prognostic marker for CXL effectiveness. This could imply a 
potential refractive implication of DL depth if associated with higher densitometry values of 
the mid stroma.  
Clearly, in addition to the important morphological meaning as “boundary line” between CX-
linked and non-CX-linked stroma and the potential refractive impact, the depth of the DL has 
important implications on the biomechanical changes induced by CXL. 
Wollensak et al85 ex vivo stress strain tests on CXL corneas demonstrated a correlation DL 
depth and corneal stiffening. As previously mentioned, ex vivo tests are not able to quantify 
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the level of stiffening and strengthening, but they provide an indication of biomechanical 
changes. Non-destructive Brillouin microscopy demonstrated a biomechanical stiffening of 
the stroma after TE-CXL for cases where the DL was invisible, poorly visible or located 
below 100µm (measured with epithelium), about 70% less than the conventional epithelium-
off Dresden protocol.27 
The biomechanical implication of the DL depth can be explained by considering that ectasia 
originates in almost all cases from the posterior float of the cornea.86 The well-known 
structure of the human corneal stromal has been revealed by many studies based on X ray 
diffraction87-91. The anisotropy, the orientation, the intersection and the distribution of corneal 
lamellar structure and collagen fibrils interweaves are not uniform across the thickness of the 
stroma, but the reinforcing structure characterizes a stronger cornea in the anterior third (160-
180µm) and a progressively weaker stroma in the posterior part (over 160-180). The 
particular structure explains the fact that most of ectatic corneas treated with Epi-Off S-CXL 
were stable in the long term follow-up5, even in paediatrics patients 18 years and younger6, 
whereas after Epi-On treatments showing a superficial DL, with a depth from the epithelial 
surface less than 200 µm and unevenly detectable, had almost 50% of unstable cases with the 
need to repeat CXL procedures.25,18,35,36  
A supporting prove was provided by the stress-strain tests performed by Kohlhaas et al92 at 
different depths, showing that the CXL treatment of the cornea with riboflavin and UVA 
significantly stiffened the cornea only in the anterior 200µm. This depth-dependent stiffening 
effect may be explained by the absorption behaviour for UV-A in the riboflavin-treated 
cornea: 70% percent of UV-A irradiation was absorbed within the anterior 200 µm and only 
30% reached the deeper layers.  
Clearly, the goal of a CXL procedure is the halt of the progression of keratectasia. The 
refractive improvement represents an eventual additional gain. There is general consensus 
regarding to the fact that the efficacy of S-CXL is reflected by a deep DL which implies better 
clinical results. The deeper the DL the stronger the overall biomechanical effect. By 
accounting that the posterior stroma beyond 160 µm depth is the weakest portion and that 
ectasia originates from the posterior side of the cornea, optimization models of CXL and 
clinical results recommend to stiffen the cornea by reaching at least a stromal DL depth of 
200 µm or more. 
It has been observed that the biomechanical effect does not necessarily correlates with the 
UV-A dose when the treatment time or UV-A dose exceed certain limits. For example, the 
biomechanical effect obtained after 60 min irradiation is equivalent and not significantly 
increased with respect to the effect obtained after 30 min irradiation as described in the 
Wollensak’s protocol1. Moreover, the photo-oxidative damage would not diminish between 
30 and 60 minutes UV-A irradiation, because cells that become apoptotic after 30 min 
irradiation will not recover, and a higher cumulative UV-A dose is delivered to the 
endothelium.  
Interestingly, on AS-OCT immediately after hydration, Wollensak et al13 observed at the 
depth of 540 µm in the treated portion of the anterior stroma a pronounced line, correlating 
with the combined area of the anterior intensely and less intensely CX-Linked intermediate 
layers. Since hydration is a very sensitive parameter, it seems possible that the line includes 
the intensely CX-Linked stroma and the less intensely CX-Linked intermediate layers.  
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Lanchares et al.93 did not observed CXL effects due to the increase of the cross-linking time 
to 60 minutes. Nevertheless, they found that for the same UV-A dose of 5.4J/cm², both the 
CXL efficacy and the increase of the elastic modulus show a reduction at a higher irradiance. 
This would apparently invalidate the Bunsen-Roscoe law, because the biomechanical effect of 
CXL reduces at a higher irradiance.  
To date, the in-vivo correlation between DL depth and corneal biomechanics cannot be 
estimated by means of a simple relationship. According to Fuchsluger et al94 the 
biomechanical parameters of the cornea in healthy and KC eyes, CXL treated or not, can be 
evaluated by means of ultrahigh-speed Scheimpflug measurements (Corvis ST). A newly 
introduced parameter, namely the difference between inward applanation length and outward 
applanation length (A1L – A2L), indicated highly significant differences between CX-linked 
corneas and untreated KC or healthy corneas. Moreover, the velocity at the second 
applanation (A2V) and the deformation amplitude (DA) were significantly increased in 
crosslinked KC eyes with respect to both untreated KC and healthy control eyes. Also the 
radius at the maximum curvature was significant among all groups. Inward applanation length 
(A1L) was significantly increased in controls, whereas outward applanation length (A2L) was 
significantly reduced in CX-Linked KC eyes with respect to both untreated KC and healthy 
control eyes.  
CXL essentially improves corneal stiffness by increasing the percentage of links among 
stromal collagen fibres basically due to a photo-oxidative process followed by reinforcement 
of CPC and ECM, leading to a local increment of the stromal stiffness. Since the DL is a clear 
mark of the penetration of the CXL-induced photo-oxidative damage, an evident, although not 
linear, correlation between the DL depth and the local increase of the stromal stiffness does 
exist.  
The elastic modulus (E-modulus) measures the ability of a material to oppose the 
deformation, and in biological tissues it is increasing with the level of deformation. In the case 
of the cornea, it increases with the IOP and, at high deformations, it modifies in time 
revealing viscosity. The corneal stiffness is a more general term that indicates the propensity 
of the cornea, thought as a structure, to oppose the change of its geometry under the effect of 
external actions. The corneal stiffness depends not only on the elastic modulus, i.e. on IOP 
and time, but on many other geometric parameters, listed as follows, in order of decreasing 
importance: white-to-white distance (WTWD), mean curvature (K Avg), pachymetry, and 
scleral connection.  
CXL increases the E-modulus only of the anterior portion of the stroma up to the DL, leading 
to a modification of the overall corneal stiffness. However, the resulting increase of the 
corneal stiffness is not linearly dependent on the DL depth, because CXL acts only on a 
portion of the thickness, making the structure inhomogeneous.  
It follows that the simple geometrical interpretation of the whole dynamic deformation of the 
cornea, as induced by a soliciting force by using air-puff tonometry devices94, 95, cannot 
provide a direct estimate of the actual value of the E-modulus of the cornea, for two main 
reasons. First, the E-modulus across the cornea is not uniform, in particular in pathologic 
corneas. Second, the motion of the cornea under the dynamic test depends not only on the E-
modulus, but also on the geometric parameters listed above. It is therefore hard to try to 
establish a correlation between the global deformation of the cornea during the air-puff test 
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and the E-modulus; even harder to find a correlation between the global deformation and the 
DL depth.  
In comparing pre and post-CXL corneas, the parameters of the air puff test based exclusively 
on the analysis of the geometrical changes of the cornea during the motion can only provide a 
general indication of the modification of the stiffness, but they will not be able to quantify the 
change on E-modulus and thus to provide a meaningful estimate of the biomechanical effects 
of the CXL. 
So far, the most reliable approach to the estimate of the biomechanical effects of CXL must 
be based on numerical analysis using realistic geometrical and material models of the cornea, 
e.g., the finite element analysis (FEA) 84, 103, 104, that accounts for the exact geometry, the 
complex microstructure of the stroma, and furthermore for the presence of the fluids filling 
the anterior chamber105, 106,107. Numerical approaches must be combined with experimental 
testing conducted with advanced devices conceived to provide accurate information on the 
variability of the material parameters of the stroma, such as the ones based on Bruilloin 
microscopy27. Such approaches are under development but not available yet for clinical 
practice. 
Up to now, no fast, inexpensive, and patient-friendly method is available to control under 
clinical conditions the biomechanical efficacy of the CXL treatment but the depth of the DL.  
Obviously, DL depth is an immediate indicator unable to predict the long term response to 
CXL in terms of tissue stabilization, which is strongly affected also by many biological, 
genetic, and environmental factors.96-100 Each KC is different from any other, and 
characterized by different ectasia progression indices related to different genetic penetrance, 
phenotypic expression and comorbidities,96 environmental factors such eye-rubbing, patient’s 
age, allergy97 and presence of hormones (cortisol, thyroxin, estrogens, androgens, progesteron, 
prolactin).98-102  
All these factors inevitably have a great influence on the time evolution of KC pathology and 
also in the clinical response to any CXL treatment. None of them, however, affects the 
fundamental significance of the DL to assess the evidence of CXL penetration and to quantify 
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